STADA Arzneimittel AG, DE0007251803

STADA Arzneimittel AG, DE0007251803

04.07.2017 - 00:26:11

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

Bad Vilbel, July 3, 2017 - STADA Arzneimittel AG confirms that Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, gave notice to be considering to submit an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to make a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA is currently assessing whether the company would give its consent to the exemption from the exclusion period and will keep both the capital market and the public updated on further progress in this regard, in line with the applicable legal requirements.

Contact: STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de

Or visit us on the internet at www.stada.com

04-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel

Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of Announcement DGAP News Service

589275  04-Jul-2017 CET/CEST

@ dgap.de